Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Albene Kokocinski

Internal Medicine Chicago, IL Medical Doctor

NPI 1053346221 CMS profile 47913

1725 W Harrison, Suite 318, Chicago, IL 60612

Open in the dashboard

General payments

$5,602

272 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Albene Kokocinski of Chicago, IL is reported in the CMS Open Payments database as having received $5,602 across 272 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $253 11
2023 General $880 39
2022 General $943 45
2021 General $1,350 69
2020 General $868 45
2019 General $1,308 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Albene Kokocinski
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Albene Kokocinski were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Albene Kokocinski Internal Medicine median Middle half National median
2019 $1,308 $159 $48–$570 $163
2020 $868 $119 $33–$402 $114
2021 $1,350 $135 $37–$521 $132
2022 $943 $141 $42–$496 $149
2023 $880 $149 $45–$519 $160
2024 $253 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Novo Nordisk Inc $942 43 payments
  2. Pfizer Inc. $929 38 payments
  3. AbbVie, Inc. $911 47 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $366 16 payments
  5. Amgen Inc. $346 19 payments
  6. Novartis Pharmaceuticals Corporation $315 16 payments
  7. Kowa Pharmaceuticals America, Inc. $193 9 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $183 11 payments
  9. Astellas Pharma US Inc $178 5 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $175 12 payments
  11. Other $1,063 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $5,503 271 payments
  2. Education $99 1 payment
Products named General payments · program years 2019–2024
  1. Ozempic $511 23 payments
  2. ELIQUIS $497 18 payments
  3. RYBELSUS $430 19 payments
  4. LINZESS $346 18 payments
  5. CREON $339 19 payments
  6. Prolia $301 17 payments
  7. ENTRESTO $290 15 payments
  8. EVENITY $289 16 payments
  9. Wegovy $202 10 payments
  10. JARDIANCE $196 9 payments
  11. Other $4,903 246 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

1,601

Median for Internal Medicine: 777

Drug cost

$71,493

Median for Internal Medicine: $73,373

Branded share of claims

10.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 33 $40,377
Breo Ellipta Fluticasone/Vilanterol Brand 13 $11,563
Levothyroxine Sodium Generic 138 $2,107
Atorvastatin Calcium Generic 176 $1,757
Amlodipine Besylate Generic 136 $1,621
Synthroid Levothyroxine Sodium Brand 31 $1,553
Metoprolol Succinate Generic 57 $1,011
Losartan Potassium Generic 108 $952
Pantoprazole Sodium Generic 38 $794
Simvastatin Generic 61 $744

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$67,025

Medicare's payments for the services billed

Medicare patients

218

Average age 74

Services billed

834

162 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 66%
Ischemic heart disease 25%
Diabetes 19%
Osteoporosis 19%
Depression 17%
Cancer 16%
Chronic kidney disease 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $107
$107 — —
ELIQUIS
  • PFIZER INC. $26
$26 — —
NURTEC ODT
  • PFIZER INC. $26
$26 — —
PAXLOVID
  • PFIZER INC. $26
$26 — —
RYBELSUS
  • Novo Nordisk Inc $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

272 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record